Evidence map›Paper›PMID 26557765›Full record

ArticleContemporary oncology (Poznan, Poland)2015

Radiation enhancing effects of sanazole and gemcitabine in hypoxic breast and cervical cancer cells in vitro.

Yue-Can Zeng, Rong Wu, Yu-Ping Xiao, Yan Xin, Feng Chi, Rui Xing, Ming Xue, Nai-Qian Wang

Open access · goldAbstract read
In one paragraph

Article in Contemporary oncology (Poznan, Poland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Hypoxia-active nanoparticles used in tumor theranostic.International journal of nanomedicine · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yue-Can ZengDepartment of Medical Oncology, Shengjing Hospital of China Medical University, Shenyang, China ; Cancer Insititute, No. 1 Hospital of China Medical University, Shenyang, China.
Rong WuDepartment of Medical Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
Yu-Ping XiaoCancer Insititute, No. 1 Hospital of China Medical University, Shenyang, China.
Yan XinCancer Insititute, No. 1 Hospital of China Medical University, Shenyang, China.
Feng ChiDepartment of Medical Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
Rui XingDepartment of Medical Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
Ming XueDepartment of Medical Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
Nai-Qian WangCancer Insititute, No. 1 Hospital of China Medical University, Shenyang, China.
China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aim of the studySanazole and gemcitabine have been proven clinically as hypoxic cell radiosensitisers. This study was conducted to determine the radiation enhancing effects of sanazole and gemcitabine when administered together at relevant concentrations into hypoxic human MCF-7 and HeLa cells. MATERIAL AND

methodsA 3-(4,5 dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) assay was used to evaluate the number of surviving cells. Cell cycle was determined by flow cytometry. Cell surviving fractions were determined by the standard in vitro colony formation assay.

resultsThe cell colony formation assay indicated that the radiosensitivity of hypoxic MCF-7 and HeLa cells was enhanced by sanazole or gemcitabine. The combination of the two drugs displayed significant radiation enhancing effects at the irradiation doses of 6, 8, and 10 Gy in both cell lines, which were arrested in the S phase.

conclusionsThis study indicated that the co-administration of the two drugs may result in a beneficial gain in radio-therapy for hypoxic breast cancer and cervical cancer.

Indexed as

gemcitabineHeLa cellsMCF-7 cellsradiosensitiserSanazole

Identifiers

PMID26557765
PMCPMC4631282
OpenAlexW2179773813

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.